Ulcerative Colitis

ORLANDO — Adding genetic testing to the management of patients with inflammatory bowel disease may present an opportunity to determine which patients are at greater risk for loss of response and help select the best therapies for each individual patient, according to an expert.

ORLANDO — Whether reactive or proactive, therapeutic drug monitoring has become an important part of inflammatory bowel disease care, according to experts.

ORLANDO — Inflammatory bowel disease is a life-altering condition that takes a lifetime of care. Adding it to another life-altering disease, like cancer, makes management decisions much more complicated for physicians, according to experts.

ORLANDO — Surgeons have become an important part of an inflammatory bowel disease care team. While there were only a handful of surgeons who participated in meetings with patients, Feza H. Remzi, MD, of NYU Langone School of Medicine, said it is now much more common.

The FDA on Thursday approved Xeljanz extended release 11 mg and 22 mg tablets for the once daily treatment of adults with moderately to severely active ulcerative colitis, following an inadequate response or intolerance to previous TNF blocker therapy, according to a press release from the manufacturer.

The FDA has approved the fourth biosimilar to infliximab, infliximab-axxq, for all eligible indications of the biologic product.

Patients with inflammatory bowel disease who received long-duration vancomycin as treatment for Clostridioides difficile infection had lower recurrence rates compared with patients who receive shorter durations of the drug, according to study results.

SAN ANTONIO — The odds of inpatient mortality were nearly four times higher among geriatric adults than adults aged younger than 75 years who were admitted to a hospital primarily for inflammatory bowel disease, according to data presented at the American College of Gastroenterology Annual Meeting.

SAN ANTONIO — Entyvio was associated with significantly fewer serious adverse events and serious infections compared with anti-TNF therapy in biologic-naive patients with inflammatory bowel disease, according to data from the EVOLVE trial presented at the American College of Gastroenterology Annual Meeting.

SAN ANTONIO — Older patients with Crohn’s disease were less likely to receive biologic agents and more than twice as likely to receive mesalamine compared with younger patients, according to data presented at the American College of Gastroenterology Annual Meeting.